

---

**From:** [REDACTED]  
**Sent:** Friday, 29 July 2022 12:06 PM  
**To:** Exemptions; Jones, Gavin  
**Cc:** [REDACTED]  
**Subject:** Medicines Australia-ACCC Interim Authorisation- AA1000579-Monthly report-30 June to 29 July 2022

Dear ACCC Exemptions Team,

In relation to the ACCC Interim Authorisation AA1000579 ( 29 September 2021) and, specifically, in accordance with the Conditions of that Authorisation at paragraph 23, Medicines Australia provides the following monthly report on activities related to the Proposed Conduct.

In the period of 30 June 2022 to 29 July 2022, no meeting, discussion, development or decision between MA/GBMA Working Group members in relation to the Proposed Conduct took place.

Medicines Australia's next monthly update will cover the period of 30 July 2022 to 29 August 2022. Additional updates will be provided to the ACCC as required and in accordance with Medicines Australia's obligations under the authorisation.

We also consent to this email being published on the public register, with the appropriate privacy redactions.

This response was drafted by Medicines Australia in consultation with [REDACTED], CEO of Generic and Biosimilar Medicines Association.

Yours sincerely

[REDACTED]

[REDACTED]  
**Senior Executive Assistant**

[REDACTED] | [REDACTED]  
📍 17 Denison Street, Deakin ACT 2606



*In the spirit of reconciliation Medicines Australia acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.*